fulvestrant accord fulvestrant 250 mg/5 ml solution for injection pre-filled syringe
accord healthcare pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: benzyl alcohol; castor oil; benzyl benzoate; ethanol - fulvestrant accord is indicated for the treatment of postmenopausal women with: ? hormone-receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy. ? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.
fulvestrant 250 mg solution for injection in pre-filled syringe
reddy holding gmbh - fulvestrant - solution for injection in pre-filled syringe - fulvestrant
fulvestrant-aft fulvestrant 250 mg/5 ml solution for injection pre-filled syringe
aft pharmaceuticals pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: ethanol; benzyl alcohol; benzyl benzoate; castor oil - fulvestrant-aft is indicated for the treatment of postmenopausal women with:,? hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy.,? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.
fulvestrant sandoz fulvestrant 250 mg/5 ml solution for injection in pre-filled syringe
sandoz pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: castor oil; benzyl alcohol; benzyl benzoate; ethanol - fulvestrant sandoz is indicated for the treatment of postmenopausal women with: ? hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy. ? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.
fulvestrant teva 250 mg solution for injection in pre-filled syringe
teva b.v. - fulvestrant - solution for injection in pre-filled syringe - 250 milligram(s) - anti-estrogens; fulvestrant
fulvestrant rowex 250 mg/5 ml solution for injection in pre-filled syringe
rowex ltd - fulvestrant - solution for injection in pre-filled syringe - 250 mg/5ml - anti-estrogens; fulvestrant
fulvestrant 250 mg solution for injection in pre-filled syringe
accord healthcare ireland ltd. - fulvestrant - solution for injection in pre-filled syringe - 250mg millilitre(s) - anti-estrogens; fulvestrant
fulvestrant injection solution
sandoz canada incorporated - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents
fulvestrant accord 250 mg inj. sol. i.m. pre-filled syr.
accord healthcare b.v. - fulvestrant 250 mg - solution for injection in pre-filled syringe - 250 mg - fulvestrant 50 mg/ml - fulvestrant
fulvestrant sandoz 250 mg inj. sol. i.m. pre-filled syr.
sandoz sa-nv - fulvestrant 250 mg/5 ml - solution for injection - 250 mg - fulvestrant 50 mg/ml - fulvestrant